Interest in Tyk2 might soon tick up
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Aducanumab: this time it’s personal
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.
Anti-amyloid approaches come back from the dead
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Post-Brexit device rules risk the UK falling behind
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Ionis joins the inhaled cystic fibrosis therapy race
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
J&J and Novavax push Covid-19 vaccine candidates into late-stage testing
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
